Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.
武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

VOLUNTARY ANNOUNCEMENT

Y225 "EMICIZUMAB INJECTION" RECEIVES IND APPROVAL FROM NMPA

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors of the latest business updates of the Company.

The Company is pleased to announce that on December 23, 2025, the Investigational New Drug ("**IND**") application for its biosimilar Y225 has been approved by the National Medical Products Administration ("**NMPA**") of the People's Republic of China.

Y225 is a biosimilar of Hemlibra® (emicizumab injection, anti-FIX and FX), a bispecific antibody used for the treatment of hemophilia A. Hemophilia A is a hereditary bleeding disorder caused by a deficiency of coagulation factor VIII, which may result in impaired blood clotting. This condition prevents spontaneous hemostasis and may lead to recurrent bleeding episodes, severe complications, and even death in severe cases. Current clinical practice primarily relies on plasma-derived or recombinant coagulation factor VIII products for prophylactic administration and post-hemorrhage treatment. However, more than 20% of patients develop inhibitors against coagulation factor VIII, which reduces treatment effectiveness. An originator drug, Hemlibra®, is currently the only bispecific antibody approved globally for prophylactic treatment of patients with hemophilia A, with or without coagulation factor VIII inhibitors. It offers advantages such as extended dosing intervals of up to once every four weeks and subcutaneous administration. However, its high treatment cost renders the medication inaccessible to patients, and Hemlibra® is subject to extensive patent protection and technological barriers, with its registered series of patents extending the product's protection period to 2038. Through independent innovation, the Company has broken through the formulation patent of this patented product, enabling Y225 to potentially enter the market seven years ahead of schedule. Y225 is expected to become one of the first biosimilar of Hemlibra® to be launched in China, filling the gap in the domestic market for high-barrier bispecific monoclonal antibody biosimilars.

This approved clinical trial is a randomized, double-blind, single-dose, parallel-group study evaluating the bioequivalence of Hemlibra® and Y225 in healthy adult male subjects. This trial is led by Dr. Huang Chaolin (黃朝林), Director of Wuhan Jinyintan Hospital (武漢市金銀潭醫院), as the principal investigator.

On June 17, 2025, the Company formally entered into a strategic cooperation agreement with Hubei Jiangxia Laboratory (湖北江夏實驗室). Leveraging Hubei Jiangxia Laboratory's strengths in cutting-edge scientific research, as well as the Company's expertise and platform capabilities in antibody drug R&D and industrialization, both parties will jointly establish an Antibody Drug Development and Achievement Transformation Center. The collaboration will focus on innovative antibody molecular design, efficient production process development, and clinical research, with our in-progress projects Y225 as the initial cooperation priorities. This partnership aims to continuously advance related R&D and transformation processes, thereby improving the overall R&D efficiency and strengthening the long-term industrialization potential of the Company's pipeline.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that Y225 will ultimately be successfully developed and marketed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, December 24, 2025

As of the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive Directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.